How OSF HealthCare and Regroup Therapy Virtualized Mental Health Treatment

Posted June 22, 2017
By Devon Leichtman
Associate Marketing Manager – MATTER

When OSF HealthCare developed their innovation model, they turned to a world outside of healthcare for inspiration. Borrowing from such non-healthcare companies as Google, Apple, and Caterpillar, OSF CEO Kevin Schoeplein  along with President Sister Diane Marie, Chief Strategy Officer Michelle Conger, and Senior Vice President and Chief Transformation Officer Dr. Jeffry Tillery  deployed an innovation team with the freedom to operate separately from the rest of the organization.

OSF’s innovation team focused on building a culture that would allow them to operate more like fast-moving tech companies. According to Matthew Warrens, vice president of innovation partnerships, “tech is all about ‘fail and fail quickly’” – a mindset that has, for good reason, never been popular in healthcare. The idea of “embracing failure” does not come naturally in an industry where failure can mean deteriorating health outcomes and lost lives.

But the OSF innovation leadership team, which includes Warrens and Innovation Partnerships Director Rob Jennetten, understood that the tech industry’s strategy for developing innovative ideas and disrupting existing markets – casting a wide net and expecting many solutions to fail – could work in healthcare if they set it up correctly. And in addition to building their internal capabilities, OSF looked externally for partners to help them with their mission. OSF was a founding partner of MATTER, where they have connected with dozens of leading-edge healthcare startups.

One of the companies they met through their relationship with MATTER is Regroup Therapy, a telemedicine solution that helps healthcare facilities augment their behavioral health capabilities. For most patients, seeing a behavioral health specialist – even if only for a quick consultation – is a painful process, requiring a referral from a primary care physician, a separate appointment, and other out-of-pocket expenses. David Cohn founded Regroup Therapy in 2012 to use telemedicine to make behavioral healthcare more accessible to patients.

OSF initially moved forward by piloting Regroup Therapy’s “doc-to-doc” model of telemedicine. It works like this: if a clinician needs a behavioral health consultation for a patient (or if a patient requests one), the doctor can use Regroup Therapy’s software to immediately consult a behavioral health specialist remotely. This system avoids a long and slow referral process, and keeps the patient from having to schedule a separate appointment, often in another location, with a behavioral health specialist.

The initial rollout of Regroup Therapy’s product has been promising. Recently OSF Ventures, the corporate investment arm of OSF HealthCare, led a $6.1M Series A investment to help them expand their product nationwide.

Best practices

The OSF collaboration with Regroup Therapy is validation that their innovation model is working. They have the mandate from leadership to explore novel technologies that can help them achieve their vision to transform healthcare to improve the lives for those they serve. Their innovation team has the remit to engage externally with companies such as Regroup Therapy, and the resources to bring solutions inside the system. And their investment arm, OSF Ventures, led by Vice President Stan Lynall, accelerates the growth of the most promising healthtech startups.

OSF HealthCare is currently working with a number of other MATTER member startups, and we expect to make more announcements in the coming months as these partnerships continue to develop.

How a One-year Old Startup Tackled an Industry Giant’s Problem

Posted March 22, 2017
By Devon Leichtman
Associate Marketing Manager – MATTER

This is Mike Abbadessa, senior director of medical affairs at Takeda Pharmaceuticals.

MikeAbbadessa

And this is Jason Smith, technology executive and computer scientist turned healthcare entrepreneur. He and Dr. Lev Becker founded the startup, rMark Bio, in 2015.

JasonSmith

The Problem

In early 2015, Mike’s team at Takeda was looking to identify Key Opinion Leaders (KOLs) by identifying patterns in practice. KOLs are influencers in the biochemical and pharmaceutical industries. Often KOLs are biochemical researchers who study chemical and biological interactions, and as such are often the first to know about potentially helpful or harmful interactions between chemicals.

Pharmaceutical companies consult with KOLs to ensure that the therapies they create are being used safely and are producing expected outcomes in patients. Additionally, these consultations keep the pharmaceutical company on the leading edge of new or emerging thinking about how to treat patients, as KOL’s typically operate on the frontiers.

Over the past 5 years Takeda used ready-to-use technologies to identify primarily clinical KOLs, but the results were discouraging, as these products weren’t customized to Takeda’s needs and their outputs weren’t specific enough to truly answer the company’s questions. Mike and his technology team worked to combat this lack of specificity by conducting an experiment (in collaboration with the Takeda Digital Accelerator team) with an established large-company / corporate consulting vendor to develop machine learning processes. Although the pilot provided some insights into the use of artificial intelligence (AI) for discerning specific KOL segments, the capabilities of the supplier were not the perfect fit at the time.

In 2016, Takeda, through the Takeda Digital Accelerator team, nominated Mike to spend his Fridays at MATTER as a Living Lab fellow, a program designed to encourage collaboration on common healthcare challenges between innovators within MATTER’s healthcare industry partner organizations and member startup companies.

Jason, meanwhile, was working to identify which academic researchers were studying conditions and subject matter relevant to the development of new drugs, hoping to license his product to pharmaceutical companies looking for the latest in R&D. To help this process his team was developing a deep learning platform, allowing rMark Bio to learn and adapt to what recommendations are most helpful to its users.

But while his product was promising, Jason was struggling, too. He was having trouble connecting with the pharmaceutical executives who would eventually use his product, and he ultimately didn’t know if he was building something that pharma companies would actually pay for.

The Pivot

At this point, MATTER VP of Programs Maryam Saleh recognized the potential synergies between Mike and Jason’s projects and introduced the two. The collaboration made sense on paper: Jason would get the feedback he needed, while Mike had a potential solution to the problem he’d been looking to solve.

But Mike’s problem wasn’t exactly the one Jason was solving. He needed to identify integrated delivery network and accountable care organization “KOLs,” not the academics that rMark Bio was working on identifying. After a few initial meetings, Mike realized rMark Bio’s potential for filling the gap identified from the previous experiment. Mike then pitched Jason on a big pivot: if rMark Bio could extend their platform and algorithms to identify KOLs that meet changing criteria for engagement with the Medical Affairs department, Takeda may be interested in licensing it.

It was a much broader scope than Jason and Lev had initially planned for their minimum viable product, however, they recognized that a decision-maker at one of the largest pharma companies in the world was telling them explicitly how to work with them.

So they went for it.

The Project

Because both individuals were active at MATTER, they could meet regularly. Jason learned a great deal from these meetings as he got an inside view into Takeda’s operations, previous attempts to solve the clinical KOL problem, and their decision-making process. He worked with Mike to get his product audited and accepted by Takeda’s IT. Further, he learned how to navigate the legal and procurement processes of a large pharmaceutical company.

For his part, Mike could provide insights to customize portions of rMark Bio’s identification and recommendation platform to ensure they met Takeda’s dynamic needs up front, rather than trying to force ready-to-use products into an awkward fit or struggling to wade through tons of raw data output from machine learning algorithms.

Takeda essentially had the best of both worlds: the customization and computing power of machine learning with the user interface and ease of use of ready-to-use solutions.

Today, rMark Bio and Takeda have a pilot agreement, under which rMark Bio will deploy its app to help about 20 Takeda employees identify clinical KOLs. Mike and Jason hope to continue the partnership after the pilot, and Takeda plans to be the first enterprise to license rMark Bio with the potential for 60 Takeda employees to use the technology, and perhaps even more, across the globe.

Takeaways

Both parties came away from the collaboration significantly better than before they decided to work together. Takeda essentially got a product that immediately solves an existing problem, without any up-front research and development cost. rMark Bio, meanwhile, got a product roadmap from a big company, immediately bordered their future opportunities for companies with similar challenges, received a potential customer, and gained a strong understanding of the buying and audit processes at big pharma companies.

The two learned how to “speak each other’s language” as well. Jason knows how to communicate his value proposition in a way big pharma would accept. And Mike learned to appreciate the startup “language” with which Jason communicates, embracing the genuine and open communication style that rules the startup world. Freely sharing ideas and criticisms, as he and Jason do, is a tenet of true innovation, while corporate culture tends to favor abstraction of language and obfuscation of ideas.

Jason now feels comfortable navigating the sales cycle at companies like Takeda and says it’s critical to have an internal champion, like Mike, as early as possible in the sales process.

Mike agrees. He believes his role as champion for innovation and startup liaison was critical to Takeda developing a solution for KOL identification, and says that any company looking to emulate his success with rMark Bio needs a senior executive dedicated to innovation. Further, he credits Takeda’s leadership for providing the resources and vision to support innovation projects.

MATTER’s Role

Mike and Jason’s successful collaboration is an example of exactly what we do at MATTER. Thanks to Jason’s MATTER membership, Takeda’s MATTER partnership, the Living Lab program, and Maryam’s warm introduction, Jason and Mike could work together and build something that neither could have done on his own.

Stories like Mike and Jason’s encourage the innovators here – both those working on their own startups and those within our healthcare industry partner organizations – that it is possible to break out of their individual silos and use innovation to accelerate the development of game- changing solutions that can move the industry forward.

Walgreens and Healthcare Technology Incubator MATTER Collaborate to Support Healthcare Innovation

edit-item-matter-wordpress

DEERFIELD & CHICAGO, Ill. – Dec. 20, 2016 – As Walgreens focuses on new ways to help support the development of next-generation healthcare technology, products and services, today the company joins Chicago-based healthcare incubator and innovation community, MATTER, in announcing a new strategic relationship.

Walgreens will collaborate with healthcare innovators across MATTER’s network of early-stage industry entrepreneurs and partners, who are focused on accelerating the development and growth of solutions that address industry challenges and improve care.

“We’re looking forward to working with MATTER and uncovering new innovation that can help shape the future of healthcare, technology and pharmacy,” said Brad Fluegel, senior vice president and chief healthcare commercial market development officer at Walgreens.

As part of the collaboration, Walgreens will actively contribute to MATTER’s knowledge network, providing expertise to MATTER’s curriculum, participating in mentorship, and supporting other initiatives designed to provide the incubator’s 150+ startups with the resources they need to further their businesses and connect to the broader healthcare ecosystem in the region.

Walgreens is also working closely with MATTER as a founding member of the recently launched Health Care Council of Chicago (HC3) – an organization co-created by MATTER and Leavitt Partners. HC3’s charter is to convene Chicagoland healthcare companies to expand the intellectual, technical, human and financial capital required to succeed in a value-based healthcare economy while concurrently raising Chicago’s profile as an American healthcare epicenter.

“Walgreens has been a retail pharmacy pioneer for more than a century,” said Steven Collens, MATTER CEO. “The opportunities, insights, and perspectives that Walgreens provides will prove invaluable to the innovators at MATTER and to the Healthcare Council of Chicago.”

“We look forward to supporting MATTER’s community efforts to help push the status quo of healthcare forward through innovation and technology,” said Nimesh Jhaveri, Walgreens divisional vice president, health services development. “Collectively, with MATTER and its members and partners, we will focus on helping to address some of the pressing healthcare challenges the industry is facing today, to better serve patients and our communities.”

MATTER acts as a community hub for stakeholders across the healthcare industry, from executives of established companies, to entrepreneurs building their own innovative solutions to real healthcare problems. By convening these various players together, MATTER believes the future of healthcare innovation can and will be reached more quickly and efficiently.

About Walgreens
Walgreens (www.walgreens.com), one of the nation’s largest drugstore chains, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. More than 10 million customers interact with Walgreens each day in communities across America, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens operates 8,175 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Walgreens omnichannel business includes Walgreens.com and VisionDirect.com. Approximately 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.

About MATTER
MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. More than 150 healthcare technology startups operate at MATTER, and the company partners with 11 hospitals and health systems, five universities and more than 40 industry-leading companies. By equipping, empowering and emboldening healthcare innovators, MATTER accelerates the development of technologies that solve the right healthcare problems in the right ways. For more information, visit www.matterchicago.com and follow @matterchicago.

Media Contacts:
Melissa Lederer
MATTER
melissa@matterchicago.com
(312) 543-9537

Scott Goldberg
Walgreens
scott.goldberg@walgreens.com
(847) 315-7649

MATTER Launches The OSF Simulation Stage in Partnership with OSF HealthCare

Screen Shot 2016-09-06 at 11.37.06 AM                  MATTER-Logo-POS[1]

New specialty environment at MATTER lets healthcare innovators develop ideas and test products in real-world clinical scenarios; first project will focus on hospital observation units

(CHICAGO, IL) – September 6, 2016 – MATTER, in partnership OSF HealthCare, today announced the launch of The OSF Simulation Stage at MATTER, a flexible simulation environment designed to allow early-stage healthcare technology innovators to test their products in real-world clinical environments and gain valuable feedback – knowledge they traditionally would not have the opportunity to receive until much later in the development process. The Stage, which is configurable to model a number of hospital clinical settings such as an ICU, cath lab, or procedure room, is outfitted with medical equipment from Hill-Rom and electronic health record software from Allscripts.

The OSF Simulation Stage’s first configuration will model a hospital observation room and will be the focal point of a six-month-long challenge sponsored by Hill-Rom to develop technologies to improve the efficiency, quality, and financial stability of hospital observation units. The challenge is an opportunity for innovators to develop solutions to a timely problem and gain feedback from clinicians on the front lines of delivering care. Applications from teams interested in participating must be submitted by October 15. The winning team will be presented with a cash prize. For more information, visit http://matterchicago.com/about/thestage/

“Simulation provides an invaluable opportunity for testing, training, and iteration in a safe and controlled environment,” said Dr. John Vozenilek, vice president and chief medical officer for Jump Trading Simulation & Education Center, a partnership between OSF HealthCare and University of Illinois College of Medicine at Peoria. “The friction involved in bringing new healthcare technologies to market is immense, and it’s often doubly hard for early-stage innovators to navigate the healthcare system to secure crucial pilots and gain direct feedback. The OSF Simulation Stage at MATTER eliminates this friction by accelerating the testing process and paving the way for outside evaluation to shape new ideas and iterative decisions that might otherwise not be uncovered until much later in the process – or missed entirely. We’re thrilled to partner with MATTER on this endeavor.”

“Since MATTER opened last year, we have heard from startups and innovators that they want greater access to clinical environments in which to develop ideas and test prototypes,” said MATTER CEO Steven Collens. “The OSF Simulation Stage gives them this environment and is designed to be highly flexible and adaptable to a variety of situational challenges.”

The OSF Simulation Stage is the second specialty environment that MATTER has designed to facilitate connection and collaboration between entrepreneurs and clinicians to advance healthcare. Previously, MATTER introduced the AMA Interaction Studio, in partnership with the American Medical Association, that provides an interactive environment for entrepreneurs and physicians to engage one another early on in the development of new solutions.

# # #

Media Contacts:
Melissa Lederer
MATTER
(312) 543-9537
melissa@matterchicago.com

Denise Molina-Weiger
OSF Innovation
(309) 308-9547
denise.molina-weiger@osfhealthcare.org

About OSF HealthCare
Headquartered in Peoria, OSF HealthCare is owned and operated by The Sisters of the Third Order of St. Francis, and consists of more than 18,000 employees in 115 locations, including 11 hospitals throughout Illinois and Michigan. Its physician network employs more than 1,000 primary care, specialist physicians, and advanced practice providers. More at www.osfhealthcare.org.

About Jump Trading Simulation & Education Center
Jump Trading Simulation & Education Center (Jump) is an incubator where collaboration and innovation lead the transformation of healthcare worldwide. Jump programs and objectives are key to improving the safety, effectiveness, and efficiency of care for community members across the region.
A collaboration between OSF HealthCare and University of Illinois College of Medicine at Peoria (UICOMP), Jump advances the missions of both organizations.

About MATTER
MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. More than 130 healthcare technology startups operate at MATTER, and the company partners with 10 hospitals and health systems, four universities and more than 40 industry-leading companies. By equipping, empowering and emboldening healthcare innovators, MATTER accelerates the development of technologies that solve the right healthcare problems in the right ways. For more information, visit www.matterchicago.com and follow @matterchicago.

Noted Author and Health Columnist David W. Johnson to Join Healthcare Technology Incubator MATTER as Author-in-Residence

(CHICAGO, IL) – June 29, 2016 – David W. Johnson, author of Market vs. Medicine: America’s Epic Fight for Better, Affordable Healthcare, writer of the widely read Market Corner commentaries, and founder and CEO of 4sight Health, will join healthcare technology incubator MATTER as its author-in-residence. During his year-long residency, Johnson will tell stories from the frontlines of innovation in American healthcare, blogging and writing on behalf of MATTER.

“There is no more interesting place in healthcare than MATTER,” said Johnson. “I’m tremendously excited about engaging with the talented entrepreneurs and visionaries there.”

“I’m a long-time admirer of David Johnson’s writing and the thought leadership he has demonstrated on the topic of market-driven healthcare reform,” said Steven Collens, chief executive officer, MATTER. “David’s vast knowledge of the healthcare industry and his passion for innovation and disruption to improve the status quo make him a perfect candidate to shine a light on the interesting stories coming out of our innovation community. We are honored to have him as our first author-in-residence.”

“Market-driven reform is transforming American healthcare and entrepreneurial startups are leading that charge by challenging incumbents clinging to old business models,” added Johnson. “Startups get it. In post-reform healthcare, outcomes matter, customers count and value rules.”

About David W. Johnson and 4sight Health

Johnson is the CEO and founder of 4sight Health (www.4sighthealth.com), a boutique advisory firm specializing in healthcare thought capital, strategic advisory services, and venture investing. He is the author of Market vs. Medicine: America’s Epic Fight for Better, Affordable Healthcare, author-in-residence at the Health Management Academy, and writer of the widely read Market Corner commentaries. Johnson is also an advisor, investor, and board member of a number of early-stage healthcare companies. During his 28-year investment-banking career, he managed over $30 billion in healthcare revenue bonds and led significant strategic advisory engagements for health system clients.

About MATTER

MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. More than 125 healthcare technology startups operate at MATTER, and the company partners with 10 hospitals and health systems, four universities and more than 40 industry-leading companies. By equipping, empowering and emboldening healthcare innovators, MATTER accelerates the development of technologies that solve the right healthcare problems in the right ways. For more information, visit www.matterchicago.com and follow @matterchicago.

# # #

Over 40 Ventures from 10 Midwest Universities to Participate in MATTER’s Second Annual Midwest University Healthtech Showcase

CHICAGOApril 8, 2016 – MATTER, the healthcare community hub and entrepreneurial incubator, announced today that the second annual Midwest University HealthTech Showcase will take place on Monday, April 11, 2016. The showcase will bring together early stage healthcare innovators from 10 midwestern universities to present their technologies to hundreds of healthcare investors and industry leaders at MATTER. The Midwest University Showcase is the kick-off event to the two-day MedCity INVEST Conference on April 12-13 that attracts both regional and national venture capitalists and angel investors.

“We’re looking forward to welcoming some of the brightest healthcare innovators from across the Midwest,” said Steven Collens, MATTER CEO. “Investors and industry leaders will see promising new technologies that represent real business opportunities and that will have a huge impact on health and healthcare.”

The event will showcase over 40 biopharmaceutical, medical device, and health IT innovations that are available for licensing or in the commercialization process. Participating technologies include BOLD Diagnostics, which developed a device to remotely capture blood pressure in patients with hypertension; NovaScan that commercializes a low-cost instantaneous cancer detection system; and Output Medical that automates urine output measurements to improve acute kidney injury diagnosis.

“We are extremely excited about attending the Midwest University Showcase because we see this as an ideal opportunity to validate our venture, and build the necessary connections to generate traction and move the company forward,” said Output Medical founder Dr. Jay Joshi.

Participating universities include Indiana, Illinois, Northwestern, Ohio State, Notre Dame, University of Chicago, University of Kansas, Medical College of Wisconsin, Rush University, and the Wisconsin Alumni Research Foundation. BioSTL will also participate. Several MATTER member companies, whose technologies were initiated out of participating universities, will be involved in the program.

In addition, MATTER will bring together healthcare technology investors from across the country, as well as industry professionals responsible for in-licensing and investment opportunities from companies such as Horizon Pharma, Abbott, AbbVie, Astellas, Baxalta, and Takeda.

“It’s always compelling to learn about new technologies that are being developed right in our backyard that we don’t have visibility into through our traditional channels,” said Nancy Sullivan, CEO of IllinoisVENTURES. “MATTER’s ability to convene this many healthcare innovators, industry insiders, and investors makes for a stimulating evening of discovery, networking, and opportunity,” Sullivan added.

The Midwest University Showcase is a private, invite-only event underwritten by Horizon Pharma. To see the full list of participating technologies, visit http://matterchicago.com/programs/midwest-university-healthtech-showcase/

About MATTER

MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. MATTER connects and promotes collaboration between entrepreneurs, scientists, physicians, investors and industry partners in order to bring next-generation products and services to market that improve quality of care and save lives. For more information, visit www.matterchicago.com and follow @matterchicago.

# # #

MATTER to collaborate with Abbott to bolster healthcare innovation

 Sam Dewey, Built In ChicagoJan 28th, 2016
This week, Merchandise Mart-based Matter, unveiled a collaboration with global healthcare company Abbott to spur innovation in healthcare. Together, the companies will work to fuel the development of tech that improves from health and healthcare. Abbott is one of MATTER’s eight platinum-level partners from various corners of the healthcare industry.

MATTER and Abbott to Collaborate on Next-Gen Healthcare Technologies

 

– General Manager at Chicago Inno01/27/16

MATTER, the Merch Mart-based hub for healthcare innovation, announced that it’s collaborating with Abbott, the global drug and research giant, “to accelerate the development of new technologies that improve health and healthcare.” Together, they’ll identify promising, emerging technologies that are potential candidates for commercialization. Abbott will also join MATTER as a mentor to the hub’s 115 healthtech members.

Abbott signs on to support Matter

By John Pletz, Crain’s Chicago Business

 

Abbott, one of Chicago’s biggest healthcare companies, has signed on as a top-level partner of Matter, the health-technology incubator at the Merchandise Mart.

Abbott is a platinum-level sponsor, alongside seven other healthcare heavyweights, such as AbbVie, Astellas, Blue Cross & Blue Shield of Illinois, Takeda and others.

“It’s one of the biggest healthcare brand names in Chicago,” says Matter CEO Steven Collens. “We’re thrilled to welcome them.”

Abbott was in the process of splitting into two companies as Matter was being formed. Baxter, which also underwent a breakup, has yet to sign on.

Matter, which launched a year ago, is home to 115 startups and counts about 50 industry partners.

Abbott will serve on Matter’s advisory board, which helps provide guidance on programming to help spur innovation. Companies collaborate with Matter startups, helping them sharpen their business plans and figure out how to land big customers while getting a close-up look for themselves at new technologies and disruptive ideas.

 See the full story at Modern Healthcare.

Congresswoman Robin Kelly Visits with Healthcare Innovators at MATTER

CHICAGO, Jan. 20, 2016U.S. Representative Robin Kelly (D-IL) today visited healthcare technology incubator MATTER to discuss healthcare innovation with early-stage entrepreneurs and industry leaders.

Launched in February 2015, MATTER is a community of health technology startups and industry leaders from across the ecosystem that are working together to foster innovation in health IT, medical devices, diagnostics and biopharmaceuticals.

Kellyvisit2During the visit, the Congresswomen met with Steven Collens, CEO of MATTER; Jeff Aronin, co-chair of MATTER and CEO of Marathon Pharmaceuticals, as well as representatives from AbbVie and Blue Cross, Blue Shield of Illinois, who are among MATTER’s industry partners. The discussion focused on MATTER’s mission to unite the healthcare industry in Illinois to solve tough challenges in healthcare and introduce next-generation solutions that will improve patient lives and drive economic growth.

Congresswoman Kelly also had an opportunity to tour the MATTER facility and meet with some of the entrepreneurs working at MATTER including the founders of CancerIQ, a digital health company that helps personalize cancer prevention, treatment and survivorship plans based on a patient’s individual risk factors; doc&I, a pricing software for healthcare providers aimed at giving patients the best prices for prescription drugs; and Resonance Medical, a medical device software provider whose first solution powers cochlear implants and other neuromodulation devices.

“As chair of the Congressional Black Caucus’s Health Braintrust, I’ve worked to draw attention to the true potential of innovations in health technology, and how they affect the ways healthcare is delivered and how individuals manage their own health,” said Congresswoman Robin Kelly. “To put it plainly, what the folks at MATTER are doing matters.”

“We must encourage health technology startups and increase funding for the basic sciences if we are to revolutionize healthcare policy to the benefit of vulnerable populations,” added Kelly. “From what I saw today, I’m confident that Chicago will serve as an innovation hub on the health innovation front. I will continue working in Washington to leverage the technologies that are the brainchild of MATTER’s innovators, so we can put an end to health disparities once and for all.”

Congresswoman Kelly is outspoken on the issue of healthcare disparity. She currently chairs the CBC’s Healthcare Braintrust, which works to address health disparities and improve health outcomes for all Americans. Particular areas of focus for the Congresswoman include addressing health inequality in our communities, gun safety, protecting a woman’s right to choose, keeping health care costs affordable and protecting Medicare and Medicaid for future generations.

kellyvisit3“We’re honored to welcome Congresswoman Kelly to MATTER to emphasize the importance of how industry collaboration and early-stage innovation is driving the future of healthcare,” said MATTER CEO Steven Collens. “We’re appreciative of Congresswoman Kelly’s commitment to supporting innovation and important healthcare initiatives, and we look forward to working with her as MATTER continues to grow.”

“We’re thrilled to have had an opportunity to expose Congresswoman Kelly to the incredible entrepreneurs at MATTER, who are focused on game-changing healthcare technology solutions,” said Jeff Aronin, co-chair of MATTER and CEO of Marathon Pharmaceuticals. 

About MATTER

MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. MATTER connects and promotes collaboration between entrepreneurs, scientists, physicians, investors and industry partners in order to bring next-generation products and services to market that improve quality of care and save lives. MATTER was developed by a team of entrepreneurs and industry leaders with the support of the state of Illinois. MATTER began as a project of ChicagoNEXT, Mayor Rahm Emanuel’s council on technology and innovation, which is part of World Business Chicago. For more information, visit www.matterchicago.com and follow @matterchicago.